The tumor promoter, phorbol 12-myristate 13-acetate (PMA), enhances tumor yield through an epigenetic mechanism. PMA, like another promoter, phosphatase inhibitor okadaic acid, works by maintaining proteins in a phosphorylated state. In order to identify chemicals with promoter and antipromoter effects, this laboratory has developed a standard curve of morphogenetic changes using data from precancerous cell lines that eventually became neoplastic. Using the curve as a basis of comparison, we defined the “signature” phenotype as that adopted when a cell line became neoplastic. The results of solving for signature type disclosed that the microtubule-depolymerizing compound, colchicine, had a promoter-like effect . The opposite effect was found if cells were exposed to paclitaxel (Taxol®) and colchicine . Such findings gave clinicians a rationale to test microtubule inhibitor combinations . Therapy is only effective when agents are administered nearly simultaneously. In the current work, we study the effect of inhibitor combinations on cell features defined by computer-assisted microscopy and classification methods based on latent factors.
Uppal, Sonal; Boudreau, Nancy; Wendt, Elizabeth; and Heckman, Carol, "Cell Edge Features Affected by Microtubule Inhibitor Combinations" (2006). Applied Statistics and Operations Research Faculty Publications. 3.
Microscopy and Microanalysis